[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-mellitus---type-2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-mellitus---type-2":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100650187","the-bright-study-device-name-halo-system-100650187",false,"NCT07745998","The BRIGHT Study (Device Name: HALO System)","The BRIGHT Study, an Open Label, Single-arm, Interventional, Multicenter, Prospective Study of the Diagnostic Feasibility of the HALO System, Designed to Evaluate the Safety and Performance of the HALO SYSTEM in Subjects With Diabetes Mellitus","Inclusion Criteria:\n\n* Willing to sign an informed consent form\n* Age ≥ 18 years\n* Willing to comply to study protocol requirements (study visits with frequent venous blood sampling and deliberate insulin, glucose, ketone and lactate challenges)\n* Willing to charge the SENSOR on daily basis\n* Willing not to insert their standard CGM and\u002For insulin pump in and around the SENSOR implant site (± radius 5 cm)\\[TS\\| XR1.1\\] Diagnosed with type 1 diabetes mellitus according to the World Health Organization criteria, for at least 12 months prior to screening, on CSII therapy\n\nExclusion Criteria:\n\n* Known allergy to polydimethylsiloxane (PDMS)\n* A contraindication to undergo challenging tests (i.e., ischemic heart disease, epilepsy, panhypopituitarism, hypoadrenalism, untreated hypothyroidism)\n* History of hepatitis C or HIV or other disease transmissible by blood\n* A condition requiring or likely to require magnetic resonance imaging during the study duration\n* Female participants who are pregnant, planning on becoming pregnant or nursing\n* Coagulation disorder, wound healing and bleeding disorder or taking anticoagulant medication (oral anticoagulants; antiplatelets (such as aspirin, ticagrelor are allowed).\n* Anemia identified by a haemoglobin \\\u003C14 g\u002FdL for men or \\\u003C12 g\u002FdL for women\n* The presence of any other active implanted device\n* The presence of any other CGM sensor\u002Fpump located in the lower abdomen (other location is acceptable)\n* Waist circumference of \\>120 cm\n* Any disorder, which in the investigator's opinion might jeopardise participants' safety or compliance with the protocol.","ALL","18 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of the BRIGHT study is to evaluate safety and performance of the HALO SYSTEM in subjects with diabetes mellitus. The primary objectives of this clinical investigation are 1) the evaluation of sensor's performance by demonstrating sensor's accuracy and stability and 2) to confirm safe implantation of the Sensor and safety of the device during implantation.",[26,27,28,29,30,31],"Diabetes Mellitus - Type 1","Diabetes Mellitus - Type 2","Diabetes Mellitus","Ketoacidosis, Diabetic","Hyperglycaemia (Diabetic)","Hypoglycemia (Diabetic)",[33,34,35,36,37,38,39,40],"CMM","CGM","Diabetes mellitus - type 1","Diabetes mellitus - type 2","ketoacidosis, diabetic","continuous multi-metabolite monitoring","hyperglycaemia (diabetic)","hypoglycaemia (diabetic)","NOT_YET_RECRUITING","2026-08-03",{"date":44,"type":45},"2026-08-04","ACTUAL",{"date":47,"type":20},"2026-12",{"date":49,"type":20},"2027-06",{"name":51,"class":52},"Indigo Diabetes NV","INDUSTRY",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100623850","phase-4-effects-of-semaglutide-on-clinical-outcomes-and-metabolic-inflammation-in-psoriasis-100623850","NCT07401992","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial","SEMAPSO","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years at the time of randomization.\n* Clinical diagnosis of plaque psoriasis with Psoriasis Area and Severity Index (PASI) ≥3 and body surface area (BSA) ≥3%.\n* Body mass index (BMI) ≥25 kg\u002Fm², consistent with overweight or obesity.\n* Participants with or without type 2 diabetes mellitus.\n* Participants with diabetes must be on stable antidiabetic therapy (no changes in medication or dosage within the previous 3 months) and have adequate glycemic control, defined as HbA1c ≤9.0% at baseline.\n* No use of systemic psoriasis therapies (e.g., methotrexate, cyclosporine) for at least 8 weeks prior to randomization.\n* No use of biologic therapies for at least 3 months prior to randomization.\n\nExclusion Criteria:\n\n* Diagnosis of a non-plaque psoriasis subtype, including pustular, guttate, nail, inverse, psoriatic arthritis, or erythrodermic psoriasis.\n* Pregnancy or breastfeeding at the time of screening or enrollment.\n* Insulin-dependent diabetes mellitus or current use of sulfonylureas.\n* Active malignancy at the time of screening.\n* History of thyroid neoplasia.\n* Presence of autoimmune diseases.\n* Use of systemic therapies within 8 weeks prior to randomization.\n* Use of biologic therapies within 3 months prior to randomization.\n* Renal insufficiency.\n* Heart failure.\n* Hepatic insufficiency.\n* History of pancreatitis.\n* Current treatment with other GLP-1 receptor agonists.\n* History of inflammatory bowel disease.\n* Known allergy to starch.",{"count":62,"type":20},62,[64],"PHASE4","This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid\u002Fcalcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight\u002Fobesity and\u002For type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid\u002Fcalcipotriol or placebo plus topical corticosteroid\u002Fcalcipotriol for 12 weeks. Clinical efficacy will be assessed using the Psoriasis Area and Severity Index (PASI), and quality of life will be evaluated using DLQI, PROMIS-29, and EQ-5D-5L. Systemic inflammatory markers will also be measured to assess metabolic inflammation.",[67,68,27],"Psoriasis (PsO)","Obesity & Overweight",[70,71,72,73,74,75,76,77],"clinical trial","psoriasis","dermatology","semaglutide","GLP-1","obesity","overweight","diabetes","RECRUITING","2026-02-03",{"date":81,"type":45},"2026-02-11",{"date":83,"type":45},"2026-01-15",{"date":85,"type":20},"2027-02-28",{"name":87,"class":88},"Hospital Universitario Dr. Jose E. Gonzalez","OTHER",1]